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Background
Particulate guanylyl cyclases are implicated in a growing
number of pathophysiologies and, therefore, represent an
important target class for drug development. We report
here the generation and pharmacological characterization
of three receptor guanylyl cyclase reporter cell lines.
Methods
Plasmid constructs encoding the natriuretic peptide recep-
tors GC-A and GC-B, and the heat-stable enterotoxin
receptor GC-C, were stably transfected in a parental
reporter cell line expressing the cyclic nucleotide-gated
(CNG) cation channel CNGA2, acting as the biosensor for
intracellular cGMP.
Results
In our reporter cell lines, receptor guanylyl cyclase activity
can be monitored in real-time via aequorin luminescence
stimulated by calcium influx through the CNG channel.
By using different natural as well as synthetic receptor lig-
ands of the natriuretic and guanylin peptide families, we
could show that our reporter assay monitors guanylyl
cyclase activity with unrivalled high sensitivity. Receptor
antagonists were also tested and, unexpectedly, were char-
acterized as partial agonists.
Conclusion
The results imply that our novel guanylyl cyclase reporter
cell lines are well suited for the characterization of recep-
tor pharmacology. This novel reporter system may be used
for drug discovery by (u)HTS and for natural ligand char-
acterization of guanylyl cyclase orphan receptors.
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